



Life Saving

Molecular Diagnostics

For Cancer & Diabetes

Name	Micromedic Technologies Ltd
Industry	Biotech, Molecular Diagnostics [MDx]
Type	Public [Tel Aviv Stock Exchange]
Symbol	MCTC
Pipeline	Biomarkers for major types of Cancer & Diabetes


The Company

Micromedic is a publicly traded company listed on the Tel Aviv Stock Exchange. The Company's main business is licensing, translating and commercializing of new promising early-detection and monitoring biomarkers for various clinical conditions.



Micromedic has created collaborations & strategic alliances with leading research and clinical institutes in Israel and in the US. Micromedic is currently collaborating with the Hadassah Medical Center in Jerusalem, the Tel Aviv Sourasky Medical Center, the University of Florida and The Technion-Israel Institute of Technology.

Micromedic Business Model is licensing commercialization rights from leading scientific institutes in Israel and abroad for research with business potential and "translation" into a new product with a significant market potential.



The MDx Market Potential

- **The biomarkers market grows at an annual rate of 15%**
- **Developments in the study of human genome enables the development of new and advanced biomarkers**
- **The market for cancer biomarkers is the most promising sector in the market and grows at an estimated annual rate of 34%**

Contacts:
Micromedic Technologies Ltd
Web : WWW.M-MEDIC.COM
Mail : Office@m-medic.com
Tel : 972-3-5756917



Life Saving

Molecular Diagnostics

For Cancer & Diabetes



Our Pipeline

- **Detection of Colorectal Adenoma:** Based on research by Prof. Nadir Arber from the Tel Aviv Souraski Medical Center who identified that elevated levels of CD24 are indicative of Colorectal Cancer [CRC]. CD24 is being used as the basis for a kit to diagnose colorectal adenoma which is a precursor for CRC . CRC is an aggressive type of cancer with high incidence in people over 50 years old.
- **Risk Assessment for BRCA1 and/or BRCA2 Mutations:** Based on research by Dr. Asher Salmon and Prof. Tamar Peretz from the Hadassah Medical Center in Jerusalem, who identified genes that are indicative of the presence of mutations in BRCA1 and/or BRCA2 genes. Women with BRCA mutations have a significantly higher probability of developing breast and/or ovarian cancer.
- **Risk Assessment for the Development of BONJ:** Based on research by Prof. Josef Katz from the University of Florida who identified genes that increase the risk of cancer patients receiving i.v. bisphosphonate treatment to develop BONJ (Bisphosphonate Osteonecrosis of the Jaw).
- **Detection of Type-1 Diabetes:** Based on research by Prof. Nathan Karin and Prof. Naim Shehadeh from Rambam and the Technion Medical School, who identified CCL3-autoantibodies [CCL3-AAB] as the basis for the diagnosis of Type-1 and pre-Type-1 Diabetes. CCL3-AAB has CE Mark and is approved for marketing in the EU.

Contacts:
Micromedic Technologies Ltd

Web : WWW.M-MEDIC.COM
Mail : Office@m-medic.com
Tel : 972-3-5756917

